Oura Ring Lawsuit Challenges Accuracy of Sleep Tracking Claims

The complaint targets the accuracy of the company's sleep staging feature across multiple generations of Oura Ring and the marketing built around it.

Sensor Stack vs. Clinical Baseline

A formal polysomnography protocol captures electroencephalography, electrooculography, electromyography, and electrocardiography signals — the electrophysiological inputs that define each sleep stage. The Oura Ring 5 instead ships with a photoplethysmogram (PPG) sensor using red and green LEDs, an array of temperature sensors, and a 3D accelerometer. That hardware outputs heart rate, peripheral blood oxygen saturation, breathing rate, skin temperature trends, and motion. It does not measure the brain, eye, muscle, or cardiac electrical signals used in a clinical sleep study. The lawsuit characterizes the resulting sleep staging output as AI inference built on incomplete data, stating the device is doing "guesswork as to what may be happening, based on improper inputs."

The Numbers in Dispute

Oura's published marketing for the Oura Ring 5 cites "95% Sleep Staging Accuracy compared to [a] clinical sleep lab." The complaint argues that figure is misleading because the ring's sensor inputs are not equivalent to the polysomnography inputs that clinical stage classification depends on. In a statement provided to Gizmodo, Oura said it stands behind its claims and that its sleep staging has been validated and compared favorably in multiple studies against polysomnography, the gold standard. The company referenced a dataset of over 1,200 nights informing its proprietary NSSA algorithm and a peer-reviewed paper describing the model's signal use. Oura also stated the ring is not a medical device and not a substitute for a clinical sleep study, and that it will defend against the allegations in the appropriate legal forum.

Market Context and What to Track

Consumer wearables remain a high-growth category. The Mac Observer reports the segment could generate more than $1 trillion by 2032. RamaOnHealthcare, citing a Consumer Technology Association annual outlook, describes a bullish environment for health-driven wearables with widely varying levels of clinical evidence behind competing claims. The suit seeks class certification, an injunction against the alleged false advertising, and monetary damages for affected buyers. For consumers comparing rings and watches against clinical baselines, the data shows a category where consumer-grade hardware is being benchmarked against medical-grade standards it is not engineered to meet.